Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 13
2008 24
2009 16
2010 18
2011 15
2012 22
2013 17
2014 11
2015 16
2016 16
2017 16
2018 7
2019 13
2020 24
2021 33
2022 25
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: zagouri f. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. André F, et al. Among authors: zagouri f. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Lancet. 2023. PMID: 37086745 Clinical Trial.
"The emerging role of capivasertib in breast cancer".
Andrikopoulou A, Chatzinikolaou S, Panourgias E, Kaparelou M, Liontos M, Dimopoulos MA, Zagouri F. Andrikopoulou A, et al. Among authors: zagouri f. Breast. 2022 Jun;63:157-167. doi: 10.1016/j.breast.2022.03.018. Epub 2022 Apr 1. Breast. 2022. PMID: 35398754 Free PMC article. Review.
Advances in Gynecological Cancers.
Liontos M, Fiste O, Zagouri F, Dimopoulos MA. Liontos M, et al. Among authors: zagouri f. Int J Mol Sci. 2022 May 31;23(11):6152. doi: 10.3390/ijms23116152. Int J Mol Sci. 2022. PMID: 35682831 Free PMC article.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: zagouri f. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
Defining Oligometastatic Bladder Cancer: A Systematic Review.
Bamias A, Stenzl A, Zagouri F, Andrikopoulou A, Hoskin P. Bamias A, et al. Among authors: zagouri f. Eur Urol Open Sci. 2023 Aug 22;55:28-37. doi: 10.1016/j.euros.2023.08.003. eCollection 2023 Sep. Eur Urol Open Sci. 2023. PMID: 37662704 Free PMC article. Review.
Supportive medication in cancer during pregnancy.
Zagouri F, Dedes N, Papatheodoridi A, Liontos M, Dimopoulos MA. Zagouri F, et al. BMC Pregnancy Childbirth. 2020 Dec 1;20(1):747. doi: 10.1186/s12884-020-03432-7. BMC Pregnancy Childbirth. 2020. PMID: 33261562 Free PMC article. Review.
The Role of Exercise in Cancer-Related Sarcopenia and Sarcopenic Obesity.
Papadopetraki A, Giannopoulos A, Maridaki M, Zagouri F, Droufakou S, Koutsilieris M, Philippou A. Papadopetraki A, et al. Among authors: zagouri f. Cancers (Basel). 2023 Dec 15;15(24):5856. doi: 10.3390/cancers15245856. Cancers (Basel). 2023. PMID: 38136400 Free PMC article. Review.
Prophylactic mastectomy: an appraisal.
Zagouri F, Chrysikos DT, Sergentanis TN, Giannakopoulou G, Zografos CG, Papadimitriou CA, Zografos GC. Zagouri F, et al. Am Surg. 2013 Feb;79(2):205-12. Am Surg. 2013. PMID: 23336662 Review.
Clinical Perspectives of ERCC1 in Bladder Cancer.
Koutsoukos K, Andrikopoulou A, Dedes N, Zagouri F, Bamias A, Dimopoulos MA. Koutsoukos K, et al. Among authors: zagouri f. Int J Mol Sci. 2020 Nov 22;21(22):8829. doi: 10.3390/ijms21228829. Int J Mol Sci. 2020. PMID: 33266377 Free PMC article. Review.
274 results